Impact of FGFR2/3 Activating Genomic Alterations on Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma (mUC)
Bladder cancer research: Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC) Senior author: Guru Sonpavde, MD ASCO #GU21 Abstract 472
Guru P. Sonpavde, MD was the director of the bladder cancer program at Dana-Farber Cancer Institute and was on the faculty of Harvard Medical School. He completed his medical oncology fellowship at Indiana University. His primary focus ...
